Evidence map›Paper›PMID 36983069›Full record

ArticleInternational journal of molecular sciences2023

The Major Components of Cerebrospinal Fluid Dictate the Characteristics of Inhibitors against Amyloid-Beta Aggregation.

Andrius Sakalauskas, Mantas Ziaunys, Ruta Snieckute, Agne Janoniene, Dominykas Veiveris, Mantas Zvirblis, Virginija Dudutiene, Vytautas Smirnovas

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrius SakalauskasInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-2715-067X
Mantas ZiaunysInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Ruta SnieckuteInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-4545-161X
Agne JanonieneInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Dominykas VeiverisInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Mantas ZvirblisInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Virginija DudutieneInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Vytautas SmirnovasInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-1829-5455
Vilnius University · LT

Funding

Lietuvos Mokslo Taryba 01.2.2-LMT-K-718-03-0003
6 · The paper itself

Abstract

The main pathological hallmark of Alzheimer's disease (AD) is the aggregation of amyloid-β into amyloid fibrils, leading to a neurodegeneration cascade. The current medications are far from sufficient to prevent the onset of the disease, hence requiring more research to find new alternative drugs for curing AD. In vitro inhibition experiments are one of the primary tools in testing whether a molecule may be potent to impede the aggregation of amyloid-beta peptide (Aβ

Indexed as

Alzheimer DiseaseCatechinAmyloidAmyloid beta-PeptidesHumansPeptide FragmentsAmyloidAmyloid beta-PeptidesCatechinPeptide Fragmentsaggregation kineticsamyloid-betaEGCGinhibitionnear-physiological conditionsprotein aggregationVR16-09

Identifiers

PMID36983069
PMCPMC10059578
OpenAlexW4353090728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.